| Year |
Citation |
Score |
| 2005 |
Cumbay MG, Watts VJ. Galphaq potentiation of adenylate cyclase type 9 activity through a Ca2+/calmodulin-dependent pathway. Biochemical Pharmacology. 69: 1247-56. PMID 15794946 DOI: 10.1016/J.Bcp.2005.02.001 |
0.621 |
|
| 2004 |
Cumbay MG, Watts VJ. Novel regulatory properties of human type 9 adenylate cyclase. The Journal of Pharmacology and Experimental Therapeutics. 310: 108-15. PMID 14996950 DOI: 10.1124/Jpet.104.065748 |
0.637 |
|
| 2002 |
Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology. 164: 93-107. PMID 12373423 DOI: 10.1007/S00213-002-1141-Z |
0.384 |
|
| 2001 |
Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ, DuRand CJ, Teeter MM. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Molecular Pharmacology. 60: 373-81. PMID 11455025 DOI: 10.1124/Mol.60.2.373 |
0.669 |
|
| 2001 |
Johnston CA, Cumbay MG, Vortherms TA, Watts VJ. Adrenergic agonists induce heterologous sensitization of adenylate cyclase in NS20Y-D(2L) cells. Febs Letters. 497: 85-9. PMID 11377418 DOI: 10.1016/S0014-5793(01)02442-5 |
0.701 |
|
| 2001 |
Cumbay MG, Watts VJ. Heterologous sensitization of recombinant adenylate cyclases by activation of D(2) dopamine receptors. The Journal of Pharmacology and Experimental Therapeutics. 297: 1201-9. PMID 11356947 |
0.717 |
|
| 2000 |
Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. Journal of Medicinal Chemistry. 43: 4701-10. PMID 11101361 DOI: 10.1021/Jm000339W |
0.539 |
|
| 2000 |
Schutzer WE, Watts VJ, Chapman J, Cumbay MG, Neve KA, Neve RL, Mader SL. Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity. Clinical and Experimental Pharmacology & Physiology. 27: 9-13. PMID 10696522 DOI: 10.1046/J.1440-1681.2000.03210.X |
0.642 |
|
| 1999 |
Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. The Journal of Pharmacology and Experimental Therapeutics. 289: 877-85. PMID 10215666 |
0.551 |
|
| 1998 |
Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, Neve KA. Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 8692-9. PMID 9786976 |
0.729 |
|
| 1998 |
Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, Neve KA. Selective Activation of Gαoby D2LDopamine Receptors in NS20Y Neuroblastoma Cells The Journal of Neuroscience. 18: 8692-8699. DOI: 10.1523/Jneurosci.18-21-08692.1998 |
0.723 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2016 |
Arbor SC, LaFontaine M, Cumbay M. Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. The Yale Journal of Biology and Medicine. 89: 5-21. PMID 27505013 |
0.075 |
|
| 2022 |
Hammer MF, Pan Y, Cumbay M, Pendziwiat M, Afawi Z, Goldberg-Stern H, Johnstone L, Helbig I, Cummins TR. Whole exome sequencing and co-expression analysis identify an SCN1A variant that modifies pathogenicity in a family with genetic epilepsy and febrile seizures plus. Epilepsia. PMID 35592948 DOI: 10.1111/epi.17296 |
0.047 |
|
| Hide low-probability matches. |